India Startup Builds Fingerprick Blood Test Machine

Millions of patients at small clinics across India send blood samples away and wait a full day for results that could change their treatment immediately.

Neuranics Lab wants to flip that script. The Delhi startup founded in 2021 by Ashutosh Patra and Praveen Kumar is building MorphX, a portable blood analyzer designed for places that need it most.

The complete blood count ranks among medicine's most common tests, revealing infections, anemia, and dozens of other conditions. But the machines that run these tests cost a fortune, require trained technicians, and take up space most rural health centers simply don't have.

MorphX takes a different approach. Instead of drawing vials of blood, it works from a fingerprick. Instead of shipping samples to distant labs, it delivers results in minutes right where the patient sits.

The secret lives in a microfluidic cartridge, a small plastic component with tiny channels that handle the prep work a lab technician would normally do by hand. The company calls it a lab on a cartridge.

Rather than counting cells electrically like conventional analyzers, MorphX photographs them across multiple wavelengths and uses deep learning to interpret what it sees. The system claims to measure more than 20 parameters, including cell shapes and appearances a pathologist would examine under a microscope.

That scope reportedly includes tricky cases like low platelet counts, malaria parasites, and atypical cells that stump many automated counters. These capabilities come from company descriptions and haven't been independently verified yet.

The Ripple Effect

The team has grown to around 20 people and raised between $700,000 and $1.48 million from early backers including Inflection Point Ventures, UK-India fund Pontaq, and public research incubators in Pune and Hyderabad. An HDFC corporate social responsibility grant also supported development.

A clinical trial comparing MorphX against established analyzers has been registered with India's Clinical Trials Registry, though recruitment hasn't started yet. That comparison represents a critical step toward regulatory approval.

The device has appeared at haematology conferences, but no commercial deployments or regulatory clearances have been announced. For medical devices, the path from prototype to patient typically spans years of validation and testing.

If it works as promised, MorphX could transform primary care across India and beyond, turning test results from tomorrow's problem into today's solution.